Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 250

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 250
---
ivable as a result of such fundamental
transaction by a holder of the number of Ordinary Shares represented by the Depositary Shares for which the warrant is exercisable immediately
prior to such fundamental transaction.

Transferability. Each
warrant and all rights thereunder are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment
of the warrant subject to applicable securities laws; provided, however, that the Wainwright October Warrants and Wainwright May Warrants
are subject to certain FINRA transfer restrictions. We do not intend to apply for listing of the warrants on any securities exchange or
other trading system.

No Rights as Shareholder Until Exercise. Except as set forth in the warrants, the holders of the warrants do not have any voting
rights, dividends or other rights as a holder of our capital stock until they exercise the warrants.

May 2020 United Kingdom Placing Warrants

On May
22, 2020, we issued 333,333 units, with each unit comprising one new ordinary share and one warrant. The exercise price of the warrants
is £6.80 per share, and it expires five years and six months from the issuance date. We also issued warrants to purchase a total
of 16,400 ordinary shares to Turner Pope, the placing agent, in connection with the closing of such offering, on the same terms and conditions
as the other investors in the offering.

August 2022 Warrants

On
August 3, 2022, we issued warrants to purchase 16,400 Ordinary Shares to Strand Hanson Limited, in payment for services rendered. The
exercise price of such warrants is £2.70 per share and they expire three years from the issuance date.

| 124 |

February Placement Agent Warrants

The
following is a brief summary of the February Placement Agent Warrants issued in connection with the February Private Placement and is
subject in all respects to the provisions contained in the warrant, which is filed as an exhibit to our Report on Form 6-K dated February
9, 2023. All pre-funded warrants, Series A Warrants and Series B Warrants issued in connection with the February Private Placement have
been exercised.

Exercisability.
The February Placement Agent Warrants are exercisable and expire three years from the initial exercise date. The holder shall deliver
the aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of
exercise (subject to the ‘